Patients with metastatic colorectal cancer administered bevacizumab with first-line FOLFOXIRI have significantly longer PFS and better response rates than those administered bevacizumab plus FOLFIRI, according to research presented during the 10th annual Gastrointestinal Cancers Symposium.
Bevacizumab plus capecitabine prolonged progression-free survival (PFS) in elderly patients with metastatic colorectal cancer (mCRC), according to results from the first prospective randomized study to demonstrate a benefit in this population, reported in advance of a presentation during the 10th annual Gastrointestinal Cancers Symposium.
Selective organ-sparing surgery after chemoradiation therapy is an effective treatment for patients with nonmetastatic and resectable esophageal cancer, according to findings from the long-term, multicenter phase 2 Radiation Therapy Oncology Group 0246 trial presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.
Weekly nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine significantly improved survival in patients with metastatic adenocarcinoma of the pancreas compared with gemcitabine alone, results of a global phase 3 trial reported in advance of being presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.
Patients with pancreatic cancer may benefit from pharmacogenomic (PGx) modeling that profiles response to chemotherapy, as well as from treatment with the agent S-1.
Patients with metastatic or recurrent gastrointestinal stromal tumors (GIST) who undergo surgical resection of residual lesions after disease control with imatinib have significantly better outcomes compared with those who receive imatinib alone.
Second-line docetaxel “markedly” improves overall survival without degrading quality of life among patients with relapsed esophago-gastric cancer.
A new molecular diagnostic classification system for colorectal cancers based on patterns of tumor gene expression might help identify patients who are likely to benefit from adjuvant chemotherapy.
Dr. Steven Cohen, MD, of Fox Chase Cancer Center shares his list of recommended abstracts that will be presented at the 2013 Gastrointestinal Cancers Symposium.
Please login or register first to view this content.
